Sickle hemoglobinopathy research in Zimbabwe and Zambia (SHAZ): Protocol for setting up an international Sickle Cell Disease registry

Patience Kuona, Gwendoline Q Kandawasvika, Catherine Chunda-Liyoka, Ian M Ruredzo, Pauline M Sambo, Pamela Gorejena-Chidawanyika, Hamakwa M Mantina, Takudzwa J Mtisi, Cynthia Phiri, Lawson Chikara, Natasha M Kaweme, Exavior Chivige, Jombo Namushi, Tendai Maborekeke, Uma H Uthale, Collen Masimirembwa
{"title":"Sickle hemoglobinopathy research in Zimbabwe and Zambia (SHAZ): Protocol for setting up an international Sickle Cell Disease registry","authors":"Patience Kuona, Gwendoline Q Kandawasvika, Catherine Chunda-Liyoka, Ian M Ruredzo, Pauline M Sambo, Pamela Gorejena-Chidawanyika, Hamakwa M Mantina, Takudzwa J Mtisi, Cynthia Phiri, Lawson Chikara, Natasha M Kaweme, Exavior Chivige, Jombo Namushi, Tendai Maborekeke, Uma H Uthale, Collen Masimirembwa","doi":"10.1101/2024.05.28.24308028","DOIUrl":null,"url":null,"abstract":"Of the 500 000 children born with sickle cell disease annually, most cases occur in Africa, contributing to significant morbidity and mortality associated with limited sickle cell disease (SCD) health outcomes data and reduced access to therapeutic plus preventive care. We aim to develop and manage a standardized electronic SCD registry, establish consistent standards of care (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia. This five-year program employs mixed methods that include infrastructure and skilled manpower capacity building of SCD clinics, registry, biobanking, cohort and implementation science research studies to improve SCD treatment outcomes. We are collaborating with the SickleInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the African Institute of Biomedical Sciences and Technology (AiBST) and St Jude’s Children Research Hospital. We established the SCD registry in Zimbabwe and Zambia for children and adult patients enrolling 1796/4000 (45%) participants to date. We are participating in SickleInAfrica consortium research activities, training health workers and educating SCD patient communities on SoC. This collaboration with African researchers, policymakers, health workers, and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":"76 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.05.28.24308028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Of the 500 000 children born with sickle cell disease annually, most cases occur in Africa, contributing to significant morbidity and mortality associated with limited sickle cell disease (SCD) health outcomes data and reduced access to therapeutic plus preventive care. We aim to develop and manage a standardized electronic SCD registry, establish consistent standards of care (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia. This five-year program employs mixed methods that include infrastructure and skilled manpower capacity building of SCD clinics, registry, biobanking, cohort and implementation science research studies to improve SCD treatment outcomes. We are collaborating with the SickleInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the African Institute of Biomedical Sciences and Technology (AiBST) and St Jude’s Children Research Hospital. We established the SCD registry in Zimbabwe and Zambia for children and adult patients enrolling 1796/4000 (45%) participants to date. We are participating in SickleInAfrica consortium research activities, training health workers and educating SCD patient communities on SoC. This collaboration with African researchers, policymakers, health workers, and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
津巴布韦和赞比亚镰状血红蛋白病研究(SHAZ):建立国际镰状细胞病登记处的议定书
在每年出生的 50 万镰状细胞病患儿中,大多数病例发生在非洲,由于镰状细胞病(SCD)健康结果数据有限,治疗和预防护理的机会减少,导致了严重的发病率和死亡率。我们的目标是开发和管理标准化的 SCD 电子登记系统,为患者建立统一的护理标准 (SoC),提高津巴布韦和赞比亚的 SCD 研究和生物库能力。这项为期五年的计划采用混合方法,包括提高 SCD 诊所、登记处、生物库、队列和实施科学研究的基础设施和技术人员能力,以改善 SCD 治疗效果。我们正在与非洲镰刀联盟(加纳、马里、尼日利亚、坦桑尼亚、乌干达和南非)、非洲生物医学科学与技术研究所(AiBST)和圣裘德儿童研究医院合作。我们在津巴布韦和赞比亚为儿童和成人患者建立了 SCD 登记处,迄今已有 1796/4000 人(45%)参加了登记。我们正在参与 SickleInAfrica 联盟的研究活动,培训卫生工作者,并向 SCD 患者社区宣传 SoC。这种与非洲研究人员、政策制定者、卫生工作者和 SCD 患者社区的合作将提高 SCD SoC 的使用率,并增强我们的研究能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Machine Learning Insights into HLA Noncoding Sequence Mismatches and Their Impact on DPB1 Matching in Hematopoietic Cell Transplantation Comparison of haemoglobin concentration measurements using HemoCue-301 and Sysmex XN-Series 1500: a survey among anaemic Gambian infants aged 6-12 months Detection of Common Deletion Mutations (− α3.7 and − α4.2 kb) in HBA gene and Genotype-Phenotype Correlation Multi-omic and functional screening reveal targetable vulnerabilities in TP53 mutated multiple myeloma Evaluating the Therapeutic Effects of Amino Acid Treatment on Vaso-Occlusive Pain in Sickle Cell Disease: A Systematic Review and Meta-Analysis Protocol
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1